The EPSRC Centre has two main activities within the theme of promoting the UK regenerative medicine manufacturing community:
- Promoting the UK community internationally
- Promoting the UK academic community within the UK and internationally
Promoting the UK community internationally
The EPSRC Centre's mission to Boston not only focused on biomanufacturing activities but also aimed to foster collaborations in various fields, including custom paper service. During the visit, the delegates engaged with renowned organizations and institutions, gaining valuable insights and establishing connections for future partnerships in the advancement of cell therapy and regenerative medicine. The mission delegates had the opportunity to meet with many Boston organisations, including the MIT BioMAN Research Program site, the Harvard Stem Cell Institute, the Massachusetts Life Sciences Center and companies Xcellerex and Joule Unlimited.
Importantly, the mission allowed the promotion of the UK community’s capabilities to a highly relevant US audience, sowing the initial seeds for future international collaborations.
The EPSRC Centre seeks opportunities to promote the UK community internationally – if you have a way in which we can work together, please contact us.
Promoting the UK academic community within the UK and internationally
In performing engagement work as a National Centre, the EPSRC Centre has the opportunity to promote the UK’s capability in regenerative medicine manufacturing. This is undertaken in the USA via connections through the UKTI Science and Innovation Network, and in Europe through various organisations and consortia. The EPSRC Centre is a member of the Nanomedicine European Technology Platform and engages with the EATRIS translational medicine infrastructure and EU-funded consortia including REMEDIC, TERM and Biomat-IN. Research and engagement staff attend conferences and collaboration-building events throughout Europe and overseas, disseminating our research and creating new connections with organisations.
“…we recommend that the TSB and EPSRC undertake an annual stock-take of regenerative medicine manufacturing capacity and make recommendations to BIS about future needs”
House of Lords Science and Technology Select Committee report on Regenerative Medicine, July